NCT04750772

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Comparison of Positron Nuclide Labeled DOTA-FAPI PET and FDG PET Study in Colocrectal Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the normal physiological distribution of positron nuclide labeled DOTA-FAPI PET/CT in human body and its diagnostic efficiency for colorectal cancers

Detailed description

Participants first undergo an 18F-FDG PET/CT, followed by 68Ga-FAPI04 PET/CT in groups. The purpose of the study is to explore the possibility of superiority of FAPI in diagnosis of colorectal cancer (TNM staging) by the comparison of the two tracers uptake (the maximum of standardized uptake value, SUVmax). Histopathology and conventional imaging follow-up are served as the reference standard.

Conditions

• Tumor, Solid
• Positron-Emission Tomography
• Colorectal Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	18F-FDG and 68Ga-DOTA-FAPI04 PET/CT	Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
DIAGNOSTIC_TEST	18F-FDG and 18F-DOTA-FAPI04 PET/CT	Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time

Timeline

• Start date: 2019-10-16
• Primary completion: 2022-12-01
• Completion: 2023-01-01
• First posted: 2021-02-11
• Last updated: 2022-06-27

Locations

1 site across 1 country: China